Upregulation of mirna-155 promotes tumour angiogenesis by targeting vhl and is associated with poor prognosis and triple-negative breast cancer


Upregulation of mirna-155 promotes tumour angiogenesis by targeting vhl and is associated with poor prognosis and triple-negative breast cancer

Play all audios:


ABSTRACT MicroRNA-155 (miR-155) is frequently upregulated in various types of human cancer; however, its role in cancer angiogenesis remains unknown. Here, we demonstrate the role of miR-155


in angiogenesis through targeting von Hippel-Lindau (VHL) tumour suppressor in breast cancer. Ectopic expression of miR-155 induced whereas knockdown of miR-155 inhibited human umbilical


vein endothelial cell network formation, proliferation, invasion and migration. Furthermore, mammary fat pad xenotransplantation of ectopically expressed miR-155 resulted in extensive


angiogenesis, proliferation, tumour necrosis and recruitment of pro-inflammatory cells such as tumour-associated macrophages. Expression of VHL abrogated these miR-155 effects. Moreover,


miR-155 expression inversely correlates with VHL expression level and is associated with late-stage, lymph node metastasis and poor prognosis, as well as triple-negative tumour in breast


cancer. These findings indicate that miR-155 has a pivotal role in tumour angiogenesis by downregulation of VHL, and provide a basis for miR-155-expressing tumours to embody an aggressive


malignant phenotype, and therefore miR-155 is an important therapeutic target in breast cancer. Access through your institution Buy or subscribe This is a preview of subscription content,


access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 50 print issues and online access $259.00 per year only $5.18 per issue Learn


more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS


OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS FOXO3A-DRIVEN MIRNA SIGNATURES SUPPRESSES


VEGF-A/NRP1 SIGNALING AND BREAST CANCER METASTASIS Article Open access 01 December 2020 MICRORNA-203A INHIBITS BREAST CANCER PROGRESSION THROUGH THE PI3K/AKT AND WNT PATHWAYS Article Open


access 27 February 2024 ABERRANT EXPRESSION OF MIR-133A IN ENDOTHELIAL CELLS INHIBITS ANGIOGENESIS BY REDUCING PRO-ANGIOGENIC BUT INCREASING ANTI-ANGIOGENIC GENE EXPRESSION Article Open


access 30 August 2022 REFERENCES * Baeriswyl V, Christofori G . The angiogenic switch in carcinogenesis. _Semin Cancer Biol_ 2009; 19: 329–337. Article  CAS  Google Scholar  * Bergers G,


Benjamin LE . Tumourigenesis and the angiogenic switch. _Nat Rev Cancer_ 2003; 3: 401–410. Article  CAS  Google Scholar  * Bouck N, Stellmach V, Hsu SC . How tumours become angiogenic. _Adv


Cancer Res_ 1996; 69: 135–174. Article  CAS  Google Scholar  * Folkman J, Watson K, Ingber D, Hanahan D . Induction of angiogenesis during the transition from hyperplasia to neoplasia.


_Nature_ 1989; 339: 58–61. Article  CAS  Google Scholar  * Folkman J . Role of angiogenesis in tumour growth and metastasis. _Semin Oncol_ 2002; 29: 15–18. Article  CAS  Google Scholar  *


Hanahan D, Folkman J . Patterns and emerging mechanisms of the angiogenic switch during tumourigenesis. _Cell_ 1996; 86: 353–364. Article  CAS  Google Scholar  * Allavena P, Sica A, Solinas


G, Porta C, Mantovani A . The inflammatory micro-environment in tumour progression: the role of tumour-associated macrophages. _Crit Rev Oncol Hematol_ 2008; 66: 1–9. Article  Google Scholar


  * Balkwill F . Cancer and the chemokine network. _Nat Rev Cancer_ 2004; 4: 540–550. Article  CAS  Google Scholar  * Solinas G, Germano G, Mantovani A, Allavena P . Tumour-associated


macrophages (TAM) as major players of the cancer-related inflammation. _J Leukoc Biol_ 2009; 86: 1065–1073. Article  CAS  Google Scholar  * Folkman J . Angiogenesis in cancer, vascular,


rheumatoid and other disease. _Nat Med_ 1995; 1: 27–31. Article  CAS  Google Scholar  * Risau W . Mechanisms of angiogenesis. _Nature_ 1997; 386: 671–674. Article  CAS  Google Scholar  *


Bartel DP . MicroRNAs: target recognition and regulatory functions. _Cell_ 2009; 136: 215–233. Article  CAS  Google Scholar  * Cha ST, Chen PS, Johansson G, Chu CY, Wang MY, Jeng YM _et al_.


MicroRNA-519c suppresses hypoxia-inducible factor-1alpha expression and tumour angiogenesis. _Cancer Res_ 2010; 70: 2675–2685. Article  CAS  Google Scholar  * Yamakuchi M, Lotterman CD, Bao


C, Hruban RH, Karim B, Mendell JT _et al_. P53-induced microRNA-107 inhibits HIF-1 and tumour angiogenesis. _Proc Natl Acad Sci USA_ 2010; 107: 6334–6339. Article  CAS  Google Scholar  *


Fang L, Deng Z, Shatseva T, Yang J, Peng C, Du WW _et al_. MicroRNA miR-93 promotes tumour growth and angiogenesis by targeting integrin-beta8. _Oncogene_ 2011; 30: 806–821. Article  CAS 


Google Scholar  * Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF _et al_. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. _Proc Natl Acad Sci USA_ 2005; 102: 3627–3632.


Article  CAS  Google Scholar  * Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S _et al_. MicroRNA gene expression deregulation in human breast cancer. _Cancer Res_ 2005; 65:


7065–7070. Article  CAS  Google Scholar  * Kluiver J, Poppema S, de Jong D, Blokzijl T, Harms G, Jacobs S _et al_. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and


diffuse large B cell lymphomas. _J Pathol_ 2005; 207: 243–249. Article  CAS  Google Scholar  * Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F _et al_. A microRNA expression


signature of human solid tumours defines cancer gene targets. _Proc Natl Acad Sci USA_ 2006; 103: 2257–2261. Article  CAS  Google Scholar  * Yanaihara N, Caplen N, Bowman E, Seike M,


Kumamoto K, Yi M _et al_. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. _Cancer Cell_ 2006; 9: 189–198. Article  CAS  Google Scholar  * Jiang S, Zhang HW, Lu MH,


He XH, Li Y, Gu H _et al_. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. _Cancer Res_ 2010; 70: 3119–3127. Article  CAS 


Google Scholar  * Kong W, Yang H, He L, Zhao JJ, Coppola D, Dalton WS _et al_. MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial


cell plasticity by targeting RhoA. _Mol Cell Biol_ 2008; 28: 6773–6784. Article  CAS  Google Scholar  * Kong W, He L, Coppola M, Guo J, Esposito NN, Coppola D _et al_. MicroRNA-155 regulates


cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. _J Biol Chem_ 2010; 285: 17869–17879. Article  CAS  Google Scholar  * O’Connell RM, Taganov KD, Boldin MP,


Cheng G, Baltimore D . MicroRNA-155 is induced during the macrophage inflammatory response. _Proc Natl Acad Sci USA_ 2007; 104: 1604–1609. Article  Google Scholar  * Pedersen IM, Otero D,


Kao E, Miletic AV, Hother C, Ralfkiaer E _et al_. Onco-miR-155 targets SHIP1 to promote TNFalpha-dependent growth of B cell lymphomas. _EMBO Mol Med_ 2009; 1: 288–295. Article  CAS  Google


Scholar  * Thai TH, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y _et al_. Regulation of the germinal center response by microRNA-155. _Science_ 2007; 316: 604–608. Article  CAS  Google


Scholar  * Tili E, Michaille JJ, Cimino A, Costinean S, Dumitru CD, Adair B _et al_. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their


possible roles in regulating the response to endotoxin shock. _J Immunol_ 2007; 179: 5082–5089. Article  CAS  Google Scholar  * Tili E, Michaille JJ, Wernicke D, Alder H, Costinean S,


Volinia S _et al_. Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer. _Proc Natl Acad Sci USA_ 2011; 108: 4908–4913. Article  CAS  Google Scholar  * Vigorito


E, Perks KL, Abreu-Goodger C, Bunting S, Xiang Z, Kohlhaas S _et al_. microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. _Immunity_ 2007; 27: 847–859.


Article  CAS  Google Scholar  * Babar IA, Czochor J, Steinmetz A, Weidhaas JB, Glazer PM, Slack FJ . Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells. _Cancer


Biol Ther_ 2011; 12: 908–914. Article  CAS  Google Scholar  * Suarez Y, Fernandez-Hernando C, Yu J, Gerber SA, Harrison KD, Pober JS _et al_. Dicer-dependent endothelial microRNAs are


necessary for postnatal angiogenesis. _Proc Natl Acad Sci USA_ 2008; 105: 14082–14087. Article  CAS  Google Scholar  * Coultas L, Chawengsaksophak K, Rossant J . Endothelial cells and VEGF


in vascular development. _Nature_ 2005; 438: 937–945. Article  CAS  Google Scholar  * Jain RK . Molecular regulation of vessel maturation. _Nat Med_ 2003; 9: 685–693. Article  CAS  Google


Scholar  * Kaelin WG . The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. _Nat Rev Cancer_ 2008; 8: 865–873. Article  CAS  Google Scholar  * Andorfer CA, Necela BM,


Thompson EA, Perez EA . MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer. _Trends Mol Med_ 2011; 17: 313–319. Article  CAS  Google Scholar  * Suárez


Y, Sessa WC . MicroRNAs as novel regulators of angiogenesis. _Circ Res_ 2009; 104: 442–454. Article  Google Scholar  * Kim WY, Kaelin WG . Role of VHL gene mutation in human cancer. _J Clin


Oncol_ 2004; 22: 4991–5004. Article  CAS  Google Scholar  * Zia MK, Rmali KA, Watkins G, Mansel RE, Jiang WG . The expression of the von Hippel-Lindau gene product and its impact on


invasiveness of human breast cancer cells. _Int J Mol Med_ 2007; 20: 605–611. CAS  PubMed  Google Scholar  * Greer SN, Metcalf JL, Wang Y, Ohh M . The updated biology of hypoxia-inducible


factor. _EMBO J_ 2012; 3: 2448–2460. Article  Google Scholar  * Krishnamachary B, Penet MF, Nimmagadda S, Mironchik Y, Raman V, Solaiyappan M _et al_. Hypoxia regulates CD44 and its variant


isoforms through HIF-1α in triple negative breast cancer. _PLoS One_ 2012; 7: e44078. Article  CAS  Google Scholar  * Montagner M, Enzo E, Forcato M, Zanconato F, Parenti A, Rampazzo E _et


al_. SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. _Nature_ 2012; 487: 380–384. Article  CAS  Google Scholar  * Li M, Kim WY . Two sides


to every story: the HIF-dependent and HIF-independent functions of pVHL. _J Cell Mol Med_ 2011; 15: 187–195. Article  CAS  Google Scholar  * Albini A, Tosetti F, Benelli R, Noonan DM .


Tumour inflammatory angiogenesis and its chemoprevention. _Cancer Res_ 2005; 65: 10637–10641. Article  CAS  Google Scholar  * Bergers G, Hanahan D, Coussens LM . Angiogenesis and apoptosis


are cellular parameters of neoplastic progression in transgenic mouse models of tumourigenesis. _Int J Dev Biol_ 1998; 42: 995–1002. CAS  PubMed  Google Scholar  * Skobe M, Rockwell P,


Goldstein N, Vosseler S, Fusenig NE . Halting angiogenesis suppresses carcinoma cell invasion. _Nat Med_ 1997; 3: 1222–1227. Article  CAS  Google Scholar  * Coussens LM, Werb Z .


Inflammation and cancer. _Nature_ 2002; 420: 860–867. Article  CAS  Google Scholar  * Luo JL, Maeda S, Hsu LC, Yagita H, Karin M . Inhibition of NF-kappaB in cancer cells converts


inflammation- induced tumour growth mediated by TNFalpha to TRAIL-mediated tumour regression. _Cancer Cell_ 2004; 6: 297–305. Article  CAS  Google Scholar  * Ono M . Molecular links between


tumour angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. _Cancer Sci_ 2008; 99: 1501–1506. Article  CAS  Google Scholar


  * Chang S, Wang RH, Akagi K, Kim KA, Martin BK, Cavallone L _et al_. Tumour suppressor BRCA1 epigenetically controls oncogenic microRNA-155. _Nat Med_ 2011; 17: 1275–1282. Article  CAS 


Google Scholar  * Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N _et al_. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. _J Natl Cancer


Inst_ 2003; 95: 1482–1485. Article  CAS  Google Scholar  * Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S _et al_. Prediction of BRCA1 status in patients


with breast cancer using estrogen receptor and basal phenotype. _Clin Cancer Res_ 2005; 11: 5175–5180. Article  CAS  Google Scholar  * Karginov FV, Conaco C, Xuan Z, Schmidt BH, Parker JS,


Mandel G _et al_. A biochemical approach to identifying microRNA targets. _Proc Natl Acad Sci USA_ 2007; 104: 19291–19296. Article  CAS  Google Scholar  * Keene JD, Komisarow JM,


Friedersdorf MB . RIP-Chip: the isolation and identification of mRNAs, microRNAs and protein components of ribonucleoprotein complexes from cell extracts. _Nat Protoc_ 2006; 1: 302–307.


Article  CAS  Google Scholar  Download references ACKNOWLEDGEMENTS This work was supported by grants from the National Institute of Health (CA114343 to TAS, CA115308 to JYD, and CA137041 to


JQC) and Florida Bankhead-Coley Cancer Research Program (2BB01 to JQC). AUTHOR INFORMATION Author notes * W Kong and L He: These authors contributed equally to this work. AUTHORS AND


AFFILIATIONS * Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA W Kong, L He, E J Richards, S Challa, C-X Xu & J Q Cheng * Department


of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA J Permuth-Wey & T A Sellers * Department of Women’s Oncology, H. Lee Moffitt Cancer Center


and Research Institute, Tampa, FL, USA J M Lancaster * Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA, D Coppola * Department of Immunology, H.


Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA, J Y Djeu Authors * W Kong View author publications You can also search for this author inPubMed Google Scholar * L He View


author publications You can also search for this author inPubMed Google Scholar * E J Richards View author publications You can also search for this author inPubMed Google Scholar * S Challa


View author publications You can also search for this author inPubMed Google Scholar * C-X Xu View author publications You can also search for this author inPubMed Google Scholar * J


Permuth-Wey View author publications You can also search for this author inPubMed Google Scholar * J M Lancaster View author publications You can also search for this author inPubMed Google


Scholar * D Coppola View author publications You can also search for this author inPubMed Google Scholar * T A Sellers View author publications You can also search for this author inPubMed 


Google Scholar * J Y Djeu View author publications You can also search for this author inPubMed Google Scholar * J Q Cheng View author publications You can also search for this author


inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to J Q Cheng. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare no conflict of interest. ADDITIONAL INFORMATION


Supplementary Information accompanies the paper on the Oncogene website SUPPLEMENTARY INFORMATION SUPPLEMENTARY FIGURES (PDF 253 KB) RIGHTS AND PERMISSIONS Reprints and permissions ABOUT


THIS ARTICLE CITE THIS ARTICLE Kong, W., He, L., Richards, E. _et al._ Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and


triple-negative breast cancer. _Oncogene_ 33, 679–689 (2014). https://doi.org/10.1038/onc.2012.636 Download citation * Received: 06 August 2012 * Revised: 15 November 2012 * Accepted: 16


November 2012 * Published: 28 January 2013 * Issue Date: 06 February 2014 * DOI: https://doi.org/10.1038/onc.2012.636 SHARE THIS ARTICLE Anyone you share the following link with will be able


to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing


initiative KEYWORDS * miR-155 * angiogenesis * VHL * breast cancer * inflammation